Given those functional attributes in metabolism, AMPK is a major therapeutic target for treatment of metabolic diseases (e.g., type 2 diabetes) and obesity (Viollet et al., 2009; Rojas et al., 2011; Hardie, 2013; Day et al., 2017). Here, PRKAA2 is linked to type 2 diabetes mellitus.